TABLE 1

International Society of Thrombosis and Haemostasis classification of von Willebrand disease

Type SubtypeVWD type 1VWD type 2VWD type 3
Classic1C2A2B2M2N
FrequencyCommon (70% of cases)Uncommon (25% of cases)Rare (5% of cases)
PathophysiologyMutations result in partial quantitative deficiency of functionally normal VWFQualitative defects in VWFAlmost complete quantitative deficiency of VWF
Specific mechanismDecreased synthesis of VWF due to various genetic mutationsIncreased clearance of available VWF in circulationMutations result in fewer glycoprotein Ib binding sites and less effective platelet clot formationMutations increase affinity of glycoprotein Ib binding site and clearance of high-molecular-weight multimersMutations decrease affinity of glycoprotein Ib site or decrease VWF-collagen interactionMutation in factor VIII binding site decreases affinity of VWF for factor VIII
InheritanceAutosomal dominantAutosomal dominantAutosomal dominantAutosomal dominantAutosomal dominantAutosomal recessiveAutosomal recessive
Clinical phenotypeMild to moderate mucocutaneous bleedingMild to moderate mucocutaneous bleedingModerate to severe mucocutaneous bleedingModerate to severe mucocutaneous bleedingSevere mucocutaneous bleedingHemophilialike bleedingSevere mucocutaneous and hemophilia-like bleeding
Response to desmopressinVery effective in treating minor bleeding episodesUsed to diagnose type 1C (> 30% decrease in VWF 4 hours after infusion)
Ineffective in treatment of type 1C VWD
May respond to desmopressin
Recommend challenge before therapeutic administration
Desmopressin usually contraindicated due to thrombocytopeniaMay respond to desmopressin
Recommend challenge before therapeutic administration
May respond to depression
Recommend challenge before therapeutic administration
Recommend avoiding desmopressin
  • VWD = von Willebrand disease; VWF = von Willebrand factor

  • Data adapted from reference 13.